Arrowhead Research Corporation: 10-Q Summary (Q1 Fiscal 2009)
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2008 (First Quarter of Fiscal 2009). Arrowhead Research Corporation is a development-stage nanotechnology holding company. Its strategy involves building and monetizing subsidiaries focused on healthcare (Calando Pharmaceuticals), electronics (Unidym, Inc.), and clean energy (Agonn Systems, Tego BioSciences). The Company operates with a "going concern" uncertainty due to significant operating losses and negative cash flows, necessitating a strategy of cash conservation and seeking new capital sources.
Key Financial Metrics
| Metric | Q1 2009 (Ended Dec 31, 2008) | Q1 2008 (Ended Dec 31, 2007) |
|---|---|---|
| Revenue | $701,723 | $402,861 |
| Net Loss | $(8,030,468) | $(5,233,774) |
| Operating Loss | $(8,674,681) | $(6,728,454) |
| Cash and Equivalents (End of Period) | $7,636,842 | $25,424,317 |
| Net Cash Used in Operating Activities | $(7,448,514) | $(5,831,950) |
| Total Assets | $15,390,124 | $17,255,442 |
| Total Liabilities | $8,390,049 | $4,952,833 |
| Stockholders' Equity | $5,000,075 | $12,302,609 |
Note: The filing does not provide explicit margin percentages due to the development-stage nature of the business and significant operating losses.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased 74% year-over-year, driven by $450,000 in license fees from Unidym and $166,490 in carbon nanotube sales, partially offset by a decrease in grant revenue.
- Widening Losses: Net loss increased by approximately $2.8 million. This was primarily due to a $2.1 million increase in Research and Development (R&D) expenses and a $2.3 million increase in total operating expenses.
- Cash Position: Cash reserves decreased by $2.5 million during the quarter, dropping from $10.1 million to $7.6 million.
- Debt and Financing:
- Calando raised $2.5 million via convertible promissory notes (plus $200k from Arrowhead).
- Unidym raised $2.0 million via Series C-1 Preferred Stock sale to Tokyo Electron Ventures (TEL).
- Unidym recognized a $700,000 gain from the sale of its equity interest in Ensysce BioSciences.
- Discontinued Operations: Aonex Technologies was sold in May 2008; results are now classified as discontinued operations.
Outlook, Risks, and Management Commentary
Management Strategy: The Board has approved a strategy to conserve cash and seek new capital. Measures include out-licensing technology, selling subsidiaries or non-core assets, and scaling back development efforts. If additional cash is not secured by mid-second quarter 2009, the Company plans to make further cuts to development at Calando and Unidym.
Subsidiary Updates:
- Calando: Focused on clinical trials for CALAA-01 (Phase I) and IT-101 (Phase II). Cash consumption was approximately $3.3 million in the quarter. Management is pursuing partnerships to fund operations.
- Unidym: Implemented significant cost-cutting, including terminating senior management and closing its Houston, Texas facility (subsequent to quarter-end). Cash consumption was approximately $3.4 million. The Company faces a contingent obligation to repurchase TEL Ventures' stock if specific cash flow or joint development milestones are not met by June 30, 2009.
Risks and Contingencies:
- Going Concern: Significant doubt exists regarding the Company's ability to continue as a going concern without additional financing.
- Intellectual Property: A material portion of Unidym's IP is licensed from Rice University; the license could terminate if Unidym's debts exceed assets or if it fails to pay obligations.
- Put Options: Unidym has obligations to repurchase Series C-1 Preferred Stock from TEL Ventures under specific conditions, creating a potential cash outflow of up to $2.4 million.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.6 million cash balance against the projected burn rate of Calando and Unidym, considering the recent cost-cutting measures.
- Financing Milestones: Monitor Unidym's ability to meet the $7 million cash flow requirement by June 30, 2009, to avoid the $2.4 million put option exercise by TEL Ventures.
- Calando Clinical Progress: Track the results of the Phase I trial for CALAA-01 and the Phase II trial for IT-101, as these are critical for attracting partnership capital.
- Debt Subordination: Confirm the status of Arrowhead's subordinated debt to Calando ($5.3 million) and its impact on the subsidiary's capital structure.
- Subsequent Events: Review the impact of the January 2009 closure of Unidym's Texas operations and the associated $300k-$500k charges on future liquidity.